NCT Number: NCT07264348
This study aims to evaluate the effects of a 4 month Zumba training program on cardiometabolic, hormonal, inflammatory, hepatic, renal, and functional parameters in overweight and obese women. Participants will be classified according to menopausal status (pre- or post-menopausal) and randomly assigned to an exercise group or a non-exercise control group.
Trial opening soon.
Get Notified18 year–65 year
Female
Interventional
Not applicable
Overweight and obesity are associated with metabolic dysregulation, hormonal imbalance, chronic inflammation, and reduced physical capacity. Zumba training is a dance-based aerobic exercise that can improve cardiovascular fitness, energy expenditure, and adherence to physical activity programs.
This study will assess the effects of a 4 month Zumba training program (4 sessions per week, 60 minutes per session) on: Body composition and anthropometric measures, Aerobic capacity, Hormonal profile, Lipid profile, Inflammatory biomarkers, Liver enzymes, Renal function markers, Electrolytes, Muscle enzymes, Pre- and post-training measurements will be taken under standardized conditions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants assigned to the experimental groups will perform a supervised Zumba training program for 10 weeks, with 4 sessions per week, each session lasting 60 minutes. Sessions will include a standardized warm-up (10 minutes), choreographed dance-based aerobic sequences performed at moderate intensity (40 minutes), and a cool-down with stretching (10 minutes).
Time frame: Baseline and after 4 months of Zumba intervention.
BMI calculated as weight (kg) divided by height squared (m²).
Time frame: Baseline and after 4 months of Zumba intervention.
Total body fat measured by digital scale (Tanita BC-533).
Time frame: Baseline and after 4 months of Zumba intervention.
Measured at the narrowest point between the rib cage and iliac crest using a tape measure.
Time frame: Baseline and after 4 months of Zumba intervention.
Calculated by dividing waist circumference by hip circumference.
Time frame: Baseline and after 4 months of Zumba intervention.
Measured at the widest point of the hips using a tape measure.
Time frame: Baseline and after 4 months of the intervention.
Serum prolactin concentration (ng/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum testosterone concentration (ng/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum cortisol concentration (µg/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum progesterone concentration (ng/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum estradiol concentration (pg/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum FSH concentration (mIU/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum LH concentration (mIU/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum TSH concentration (µIU/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum free T4 concentration (ng/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum PTH concentration (pg/mL).
Time frame: Baseline and after 4 months of the intervention.
Serum total cholesterol concentration (mg/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum HDL cholesterol concentration (mg/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum LDL cholesterol concentration (mg/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum triglyceride concentration (mg/dL).
Time frame: Baseline and after 4 months of the intervention.
Serum CRP concentration (mg/L).
Time frame: Baseline and after 4 months of the intervention.
ESR measured in mm/hr.
Time frame: Baseline and after 4 months of the intervention.
Includes neutrophils, lymphocytes, monocytes, eosinophils, basophils (cells/µL).
Time frame: Baseline and after 4 months of the intervention.
Serum ALT concentration measured in U/L.
Time frame: Baseline and after 4 months of the intervention.
Serum AST concentration measured in U/L.
Time frame: Baseline and after 4 months of the intervention.
Serum ALP concentration measured in U/L.
Time frame: Baseline and after 4 months of the intervention.
Serum GGT concentration measured in U/L.
Time frame: Baseline and after the 4 months of the intervention.
Serum LDH concentration measured in U/L.
Time frame: Baseline and after the 4 months of the intervention.
Serum GGT concentration measured in U/L.
Time frame: Baseline and after the 4 months of the intervention.
Total serum bilirubin concentration measured in mg/dL.
Time frame: Baseline and after the 4 months of the intervention.
Direct (conjugated) serum bilirubin concentration measured in mg/dL.
Time frame: Baseline and after 4 months of the intervention.
Serum creatinine concentration measured in mg/dL, indicator of kidney function.
Time frame: Baseline and after 4 months of the intervention.
Serum urea concentration measured in mg/dL, indicator of kidney function.
Time frame: Baseline and after 4 months of the intervention.
Serum uric acid concentration measured in mg/dL, indicator of kidney function.
Time frame: Baseline and after 4 months of the intervention.
Serum sodium concentration measured in mmol/L.
Time frame: Baseline and after 4 months of the intervention.
Serum potassium concentration measured in mmol/L.
Time frame: Baseline and after 4 months of training.
Serum calcium concentration measured in mg/dL.
Time frame: Baseline and after 4 months of training.
Serum magnesium concentration measured in mg/dL.
Time frame: Baseline and after 4 months of training.
Serum phosphate concentration measured in mg/dL.
Time frame: Baseline and after 4 months of training.
Serum CPK concentration measured in U/L, indicator of muscle damage.
Time frame: Baseline and after 4 months of training.
Serum LDH concentration measured in U/L, indicator of muscle and tissue damage.
Time frame: Baseline and after 4 months of Zumba intervention.
Measured using automated device (Omron BP652).
Time frame: Baseline and after 4 months of Zumba intervention.
Measured using an automated arm cuff (Omron BP652).
Time frame: Baseline and after 4 months of Zumba intervention.
Distance walked in 6 minutes on a 30-meter straight corridor.
Contact information is provided by the study sponsor or research team.
Wissal Abassi, Dr
CONTACT
wissal Abassi, Dr
CONTACT
High Institute of Sports and Physical Education of Kef
Other
Effects of a 4-month Intervention on Cardiometabolic, Hormonal, Inflammatory, Liver, Renal, Electrolyte, and Muscle Enzyme Parameters in Pre- and Post-Menopausal Overweight and Obese Women: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07311460
Behavior, Hormone
El Kef, Boulifa, Tunisia
View Trial DetailsNCT07264751
Exercise Training, Hormone
Gorzów Wielkopolski, Polska, Poland
View Trial DetailsNCT06504953
Hormone, Tibial Translation
Nice, Alpes-Maritimes, France
View Trial DetailsNCT07088627
Anaerobic Power, Hormone
Konya, Turkey (Türkiye)
View Trial Details